癌症相关厌食症市场－全球及区域/国家分析与预测（2025-2035）

癌症厌食症是指癌症患者出现食慾显着下降和食物摄取量减少的疾病。

这是一种复杂的、多因素引起的症状，在晚期癌症患者中尤其常见。它并非单纯的食慾不振，而是一种涉及复杂生理和心理因素的多因素综合征，在晚期癌症的后期阶段尤其常见。癌症相关性厌食症可导致营养不良和恶病质，显着降低患者的生活品质。

癌症厌食症市场是肿瘤治疗领域一个新兴且充满活力的细分市场，旨在解决癌症患者通用的厌食症和恶病质等复杂症状。该市场的成长得益于癌症发病率的上升、药物研发的进步以及对有效治疗方法厌食症及相关症状的需求不断增长。全球癌症患者数量的增加直接推动了对癌症厌食症治疗需求的成长。

近年来，食慾刺激剂和抗恶病质药物的研发推动了市场成长。此外，医护人员和患者对恶病质和厌食症的认识不断提高，促进了早期诊断和治疗。人们日益认识到恶病质是一种多因素疾病，会显着影响存活率和生活质量，这加速了该领域的研究和发展。此外，美国国家癌症研究所 (NCI) 和美国癌症协会 (ACS) 等机构的宣传宣传活动和研究津贴也有助于传播相关知识，提高诊断率，从而进一步推动了市场成长。

然而，现有药物疗效有限，且可能伴随体重增加、水肿和认知障碍等副作用，限制了部分患者的使用。此外，新型生物製药和联合治疗等创新治疗方法高成本且难以取得，尤其是在中低收入国家。而且，医疗保险体系往往无法充分涵盖这些治疗，限制了患者获得有效治疗的机会。

此外，由于缺乏国际公认的癌症相关厌食症治疗指南，在临床环境中实施标准化治疗存在障碍，导致患者治疗结果不一致。

市场的主要成长机会包括新型生物製剂、荷尔蒙疗法和食慾刺激剂的研发。例如，一些具有全新作用机制的治疗方法，如Ghrelin释放肽模拟物和肌肉生长抑制素抑制剂，正被研究作为治疗恶病质和厌食症的新方法。此外，将食慾刺激剂与现有癌症疗法（如免疫查核点抑制剂和化疗）合併使用，可望提高疗效。此类联合治疗可望同时改善多种症状，例如食慾不振、疲劳和肌肉萎缩，进而改善患者的整体治疗效果。

精准医疗在癌症厌食症治疗领域正广泛应用，治疗方法根据每位患者的基因和分子特征进行优化，从而最大限度地提高疗效并减少副作用。营养支持在癌症厌食症治疗中的重要性也日益受到重视。管饲和全肠外营养越来越多地作为药物治疗的辅助手段，帮助患者维持营养状况。

本报告检视了全球癌症厌食症市场，并总结了关键趋势、市场影响因素分析、法律制度、市场规模趋势和预测、按各个细分市场和主要国家/地区进行的详细分析、竞争格局以及主要企业的概况。

目录

执行摘要

第一章 全球癌症厌食症市场：产业展望

• 市场概览
• 按地区分類的癌症相关厌食症的流行病学分析
• 监管状态
• 主要趋势
• 临床试验分析
• 市场动态
  • 影响分析
  • 市场驱动因素
  • 市场约束
  • 市场机会

2. 全球癌症厌食症市场（按地区划分）

• 北美洲
• 欧洲
• 亚太地区
  • 市场动态
  • 市场规模及预测

第三章 全球癌症厌食症市场：竞争格局与公司概况

• 竞争格局
  • 关键策略和发展（按公司划分）
• 公司简介
  • NGM Biopharmaceuticals
  • Artelo Biosciences
  • 其他的

第四章调查方法

Global Cancer Anorexia Market, Analysis and Forecast: 2025-2035

Cancer anorexia refers to a condition characterized by a significant loss of appetite and a reduced intake of food in cancer patients. It is a complex and multifactorial symptom commonly seen in those with advanced cancer, particularly in the later stages of the disease. Cancer anorexia is not simply a lack of desire to eat, but often a profound physical and psychological condition that can contribute to malnutrition, cachexia, and a decline in overall quality of life.

The cancer anorexia market is an emerging and dynamic segment of oncology treatment, addressing the complex symptoms of anorexia and cachexia commonly observed in cancer patients. This market is influenced by several factors, including increasing cancer prevalence, advancements in drug development, and the rising need for effective treatments to manage anorexia and associated symptoms. The growing global burden of cancer significantly contributes to the rising demand for treatments addressing cancer anorexia.

Moreover, the development of new appetite-stimulating drugs and anti-cachexia medications plays a significant role in driving the market. Furthermore, increased awareness about cancer cachexia and anorexia among healthcare professionals and patients is leading to earlier diagnosis and treatment initiation. Greater recognition of cachexia as a multifactorial condition with a substantial impact on survival and quality of life has accelerated research and drug development in this area. Also, awareness campaigns and research grants from organizations like the National Cancer Institute (NCI) and American Cancer Society (ACS) are boosting knowledge and diagnosis, further fueling the market growth.

Despite advancements, current drugs often provide only limited efficacy and can be associated with side effects such as weight gain, fluid retention, and cognitive issues. This limits their widespread use in some patients, and a need for more effective therapies persists. Additionally, the cost of innovative treatments for cancer anorexia, such as newer biologic therapies and combination approaches, remains high, limiting their accessibility, especially in low- and middle-income countries. Moreover, healthcare reimbursement policies may not fully cover the expenses of these therapies, making it challenging for some patients to access effective care.

The lack of universally accepted clinical guidelines for the management of cancer anorexia makes it difficult for healthcare providers to adopt standardized treatment protocols, potentially leading to inconsistent patient outcomes.

The development of new biologics, hormonal therapies, and novel appetite stimulants represents a major opportunity in the market. For example, ghrelin mimetics and myostatin inhibitors are being explored as new treatment avenues for cachexia and anorexia. Furthermore, combining appetite stimulants with other cancer treatments, such as immune checkpoint inhibitors or chemotherapy, may offer enhanced efficacy. Combination therapies can address multiple aspects of anorexia, including appetite loss, fatigue, and muscle wasting, improving overall patient outcomes.

Precision medicine is a growing trend in the cancer anorexia market, where treatments are tailored to individual patient profiles based on genetic and molecular factors. This approach aims to optimize therapy effectiveness and minimize side effects. Moreover, there is a growing recognition of the role of nutritional support in managing cancer anorexia. The use of enteral feeding tubes and parenteral nutrition is becoming more common as an adjunct to pharmacological therapies, helping to meet the nutritional needs of patients.

The cancer anorexia market is highly competitive, with a mix of established pharmaceutical companies and emerging biotech firms innovating in the space. Many companies are focusing on developing combination therapies and biologic agents that address both the symptoms of cancer anorexia and the underlying conditions, such as cachexia. Innovative treatments, such as ghrelin mimetics and muscle-wasting agents, are being explored to target hormonal pathways and stimulate appetite in cancer patients, offering new therapeutic options. Additionally, there is growing interest in combining immune therapies with appetite stimulants to improve treatment efficacy. As research in biologic therapies and precision medicine continues, the market is evolving with more targeted and effective solutions aimed at enhancing patient outcomes and addressing the multifaceted nature of cancer anorexia and cachexia.

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Global Cancer Anorexia Market: Industry Outlook

• 1.1 Market Overview
• 1.2 Epidemiological Analysis of Cancer Anorexia, By Region
• 1.3 Regulatory Landscape
• 1.4 Key Trends
• 1.5 Clinical Trial Analysis
• 1.6 Market Dynamics
  • 1.6.1 Impact Analysis
  • 1.6.2 Market Drivers
  • 1.6.3 Market Restraint
  • 1.6.4 Market Opportunities

2. Global Cancer Anorexia Market, by Region, $Million, 2023-2035

• 2.1 North America
  • 2.1.1 Market Dynamics
  • 2.1.2 Market Sizing and Forecast
    • 2.1.2.1 North America Cancer Anorexia Market, by Country
      • 2.1.2.1.1 U.S.
• 2.2 Europe
  • 2.2.1 Market Dynamics
  • 2.2.2 Market Sizing and Forecast
    • 2.2.2.1 Europe Cancer Anorexia Market, by Country
      • 2.2.2.1.1 Germany
      • 2.2.2.1.2 U.K.
      • 2.2.2.1.3 France
      • 2.2.2.1.4 Italy
      • 2.2.2.1.5 Spain
• 2.3 Asia-Pacific
  • 2.3.1 Market Dynamics
  • 2.3.2 Market Sizing and Forecast
    • 2.3.2.1 Asia-Pacific Cancer Anorexia Market, by Country
      • 2.3.2.1.1 Japan

3. Global Cancer Anorexia Market -Competitive Landscape and Company Profiles

• 3.1 Competitive Landscape
  • 3.1.1 Key Strategies and Developments, by Company
    • 3.1.1.1 Funding Activities
    • 3.1.1.2 Mergers and Acquisitions
    • 3.1.1.3 Regulatory Approvals
    • 3.1.1.4 Partnerships, Collaborations, and Business Expansions
• 3.2 Company Profiles
  • 3.2.1 NGM Biopharmaceuticals
    • 3.2.1.1 Overview
    • 3.2.1.2 Top Products / Product Portfolio
    • 3.2.1.3 Top Competitors
    • 3.2.1.4 Target Customers/End-Users
    • 3.2.1.5 Key Personnel
    • 3.2.1.6 Analyst View
  • 3.2.2 Artelo Biosciences
    • 3.2.2.1 Overview
    • 3.2.2.2 Top Products / Product Portfolio
    • 3.2.2.3 Top Competitors
    • 3.2.2.4 Target Customers/End-Users
    • 3.2.2.5 Key Personnel
    • 3.2.2.6 Analyst View
  • 3.2.3 Others

4. Research Methodology

List of Figures

• Figure: Cancer Anorexia Market (by Scenario), $Million, 2024, 2030, and 2035
• Figure: Global Cancer Anorexia Market, 2024 and 2035
• Figure: Global Cancer Anorexia Market Key Trends, Impact Analysis, 2023-2035
• Figure: North America Cancer Anorexia Market, $Million, 2023-2035
• Figure: Europe Cancer Anorexia Market, $Million, 2023-2035
• Figure: Asia-Pacific Cancer Anorexia Market, $Million, 2023-2035

List of Tables

• Table: Market Snapshot
• Table: Global Cancer Anorexia Market, Market Dynamics, Impact Analysis
• Table: Global Cancer Anorexia Market (by Region), $Million, 2023-2035